Autolus Therapeutics PLC 8-K filings

Autolus Therapeutics announced encouraging long-term follow-up data from the FELIX trial of obecabtagene autoleucel (obe-cel) in relapsed/refractory adult B-cell Acute Lymphoblastic Leukemia (ALL), showing durable responses and potential for a survival plateau.

Autolus Therapeutics announced its first quarter 2024 financial results and provided updates on its obe-cel regulatory submissions, clinical trials, and strategic collaborations.

Autolus Therapeutics has delayed its first quarter 2024 earnings release and rescheduled its conference call due to a filing extension.

Autolus Therapeutics has appointed Michael Bonney as Chairman and Ravi Rao as a Non-Executive Director, effective April 1, 2024, following the resignation of John Johnson.

Autolus Therapeutics has determined that its previously issued financial statements for 2021 and 2022 should no longer be relied upon due to an error in accounting for research and development tax credits.

Autolus Therapeutics reports a successful 2023, highlighted by key clinical advancements, strategic collaborations, and a strengthened financial position.

Autolus Therapeutics reported its 2023 financial results, highlighted by a strategic collaboration with BioNTech and progress in its obe-cel program, including regulatory submissions and manufacturing advancements.

Autolus Therapeutics is progressing its CAR T cell therapy pipeline, highlighted by a strategic collaboration with BioNTech and positive clinical data for its lead candidate, obe-cel, in relapsed/refractory adult acute lymphoblastic leukemia (r/r ALL).

Autolus Therapeutics has priced a $350 million underwritten offering of American Depositary Shares to fund clinical development and general corporate purposes.

BioNTech and Autolus have entered a strategic collaboration to advance their CAR-T cell therapy programs, with BioNTech investing $200 million in Autolus.

The FDA has accepted Autolus Therapeutics' Biologics License Application for obecabtagene autoleucel (obe-cel) for relapsed/refractory Adult B-Cell Acute Lymphoblastic Leukemia, with a target action date set for November 16, 2024.